What is a stock summary page? Click here for an overview.
Business Description
Applied Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03828A1016
Compare
Compare
Traded in other countries / regions
APLT.USA2UV.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2019-05-13Description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 50.16 | |||||
| Equity-to-Asset | 0.06 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -13.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 43.8 | |||||
| 3-Year EPS without NRI Growth Rate | 44.1 | |||||
| 3-Year FCF Growth Rate | 43.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 20.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.39 | |||||
| 9-Day RSI | 55.7 | |||||
| 14-Day RSI | 48.08 | |||||
| 3-1 Month Momentum % | -36.21 | |||||
| 6-1 Month Momentum % | -93.3 | |||||
| 12-1 Month Momentum % | -91.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -55.7 | |||||
| Shareholder Yield % | -233.23 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 43736.49 | |||||
| Net Margin % | 88772.51 | |||||
| FCF Margin % | 38787.2 | |||||
| ROE % | -797.82 | |||||
| ROA % | -192.86 | |||||
| ROIC % | -154.32 | |||||
| 3-Year ROIIC % | 57.59 | |||||
| ROC (Joel Greenblatt) % | -12638.18 | |||||
| ROCE % | -382.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 11.19 | |||||
| Price-to-Tangible-Book | 11.19 | |||||
| EV-to-EBIT | 0.33 | |||||
| EV-to-Forward-EBIT | -0.07 | |||||
| EV-to-EBITDA | 0.33 | |||||
| EV-to-Forward-EBITDA | -0.07 | |||||
| EV-to-Revenue | 143.18 | |||||
| EV-to-Forward-Revenue | 0.92 | |||||
| EV-to-FCF | 0.47 | |||||
| Price-to-Net-Current-Asset-Value | 18.66 | |||||
| Earnings Yield (Greenblatt) % | 303.03 | |||||
| FCF Yield % | -125.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APLT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Applied Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -0.211 | ||
| EPS (TTM) ($) | -1.61 | ||
| Beta | 2 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 114.82 | ||
| 14-Day RSI | 48.08 | ||
| 14-Day ATR ($) | 0.067098 | ||
| 20-Day SMA ($) | 0.519695 | ||
| 12-1 Month Momentum % | -91.95 | ||
| 52-Week Range ($) | 0.43305 - 10.6237 | ||
| Shares Outstanding (Mil) | 116.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Applied Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Applied Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Applied Therapeutics Inc Frequently Asked Questions
What is Applied Therapeutics Inc(APLT)'s stock price today?
The current price of APLT is $0.56. The 52 week high of APLT is $10.62 and 52 week low is $0.43.
When is next earnings date of Applied Therapeutics Inc(APLT)?
The next earnings date of Applied Therapeutics Inc(APLT) is 2025-03-27 Est..
Does Applied Therapeutics Inc(APLT) pay dividends? If so, how much?
Applied Therapeutics Inc(APLT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers